The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples